Sensei Biotherapeutics (NASDAQ:FTH) CEO Anand Kiran Parikh Buys 2,806 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CEO Anand Kiran Parikh bought 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Sensei Biotherapeutics Stock Performance

Shares of FTH stock opened at $24.54 on Thursday. Sensei Biotherapeutics, Inc. has a 12 month low of $6.32 and a 12 month high of $36.76.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: CEO Anand Kiran Parikh bought 2,806 shares at $19.76 each, signaling confidence in Sensei Biotherapeutics’ outlook. CEO purchase SEC filing
• Positive Sentiment: CFO Brian C. Stephenson bought 9,230 shares at $24.36 each, a larger insider purchase that can be viewed as a strong vote of confidence from management. CFO purchase SEC filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 price target, while lifting forecasts across multiple future periods, reinforcing a bullish long-term view of the stock. HC Wainwright research note
• Neutral Sentiment: HC Wainwright’s estimates still call for losses over the next several quarters and years, so the outlook remains highly speculative and dependent on future clinical or operational progress.

Analyst Ratings Changes

Several research analysts recently commented on FTH shares. HC Wainwright initiated coverage on shares of Sensei Biotherapeutics in a report on Monday. They issued a “buy” rating and a $60.00 target price on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Finally, Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.